EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Cancer‐Control Outcomes of Japanese Vs. German Metastatic Hormone‐Sensitive Prostate Cancer Patients: A Real‐World Cross‐Country Comparison of Patients Undergoing Combination Therapies

Mike Wenzel iD, Keiichiro Miyajima iD, Maximilian Filzmayer iD, Axel S Merseburger iD, Carolin Siech iD, Benedikt Lauer, Felix K-H Chun iD, Shin Koike iD, Yoichiro Tohi iD, Takafumi Yanagisawa, Kojiro Tashiro, Takahiro Kimura und 2 weitere

International Journal of Urology · 2026

DOI: 10.1111/iju.70633 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift International Journal of Urology, 2026. Verfasst von Mike Wenzel und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Goethe University Frankfurt, University Hospital, Frankfurt, Germany. Hauptthemen laut MEDLINE: Androgen Antagonists, Antineoplastic Combined Chemotherapy Protocols, Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Differences in tumor biology, ethnicities, and healthcare structures across populations may contribute to variability in oncologic outcomes. This study compared baseline characteristics and oncologic outcomes of Japanese and German metastatic hormone‐sensitive prostate cancer (mHSPC) patients.

Methods

A pooled analysis of 1 215 mHSPC patients from Japan (JIKEI‐YAYOI database, n = 639) and Germany (FRAMCAP database, n = 576) undergoing combination therapies between 2015 and 2025 was performed. Cox regression models were used to evaluate time to castration‐resistant prostate cancer (ttCRPC) and overall survival (OS). Propensity score matched analyses (PSM) validation was performed.

Results

Japanese patients were older at diagnosis (median 73 vs. 70 years) and had higher PSA at mHSPC diagnosis (260 vs. 43 ng/mL). Moreover, Japanese patients had more frequently synchronous mHSPC (95% vs. 75%), high‐volume disease (78% vs. 54%), and visceral metastases (16% vs. 8%). ADT plus androgen receptor pathway inhibitors (ARPI) was used more frequently in Japan (76% vs. 71%), as was the combination of ADT + ARPI + docetaxel (17% vs. 11%). Conversely, ADT + docetaxel was less commonly used in Japan (7% vs. 19%). Median ttCRPC was 39 vs. 23 months, and median OS was 80 vs. 51 months (Japan vs. Germany). After adjustment for relevant clinical covariates, Japanese cohort affiliation remained an independent predictor of prolonged ttCRPC (HR 0.53, p < 0.001) and improved OS (HR 0.54, p < 0.001). PSM analyses confirmed similar findings.

Conclusions

Despite presenting with more adverse baseline characteristics, Japanese mHSPC patients demonstrated longer ttCRPC and improved OS compared with patients in Germany. These differences may reflect not only potential biological variations but also differences in treatment strategies and healthcare structures. Trial Registration Not applicable

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Androgen AntagonistsAntineoplastic Combined Chemotherapy ProtocolsProstatic NeoplasmsProstatic Neoplasms, Castration-ResistantEuropean PeopleEast Asian PeopleAgedAged, 80 and overHumansMaleMiddle AgedDocetaxelGermanyJapanPropensity ScoreProstate-Specific AntigenTreatment Outcome

Stichwörter der Autor:innen

GermanyJapanmHSPCmetastatic prostate cancersurvival

Substanzen

Androgen AntagonistsDocetaxelProstate-Specific Antigen

Autor:innen und Institutionen

  • Department of Urology, Goethe University Frankfurt, University Hospital, Frankfurt, Germany.
  • Department of Urology, The Jikei University School of Medicine, Tokyo, Japan.
  • Department of Urology, University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, Germany.
  • Martini-Klinik Prostate Cancer Center and Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
  • Department of Urology, Itabashi Chuo Medical Center, Itabashi, Japan.
  • Department of Urology, Faculty of Medicine, Kagawa University, Takamatsu, Japan.

ORCID-Profile: Mike Wenzel, Keiichiro Miyajima, Maximilian Filzmayer, Axel S Merseburger, Carolin Siech, Felix K-H Chun, Shin Koike, Yoichiro Tohi, Fumihiko Urabe

Zitieren

APA

Wenzel, M., Miyajima, K., Filzmayer, M., Merseburger, A. S., Siech, C., Lauer, B., Chun, F. K., Koike, S., Tohi, Y., Yanagisawa, T., Tashiro, K., Kimura, T., Urabe, F., & Mandel, P. (2026). Cancer‐Control Outcomes of Japanese Vs. German Metastatic Hormone‐Sensitive Prostate Cancer Patients: A Real‐World Cross‐Country Comparison of Patients Undergoing Combination Therapies. International Journal of Urology. https://doi.org/10.1111/iju.70633

Vancouver

Wenzel M, Miyajima K, Filzmayer M, Merseburger AS, Siech C, Lauer B, et al. Cancer‐Control Outcomes of Japanese Vs. German Metastatic Hormone‐Sensitive Prostate Cancer Patients: A Real‐World Cross‐Country Comparison of Patients Undergoing Combination Therapies. International Journal of Urology. 2026. doi:10.1111/iju.70633

BibTeX
@article{Wenzel2026,
  author = {Wenzel, Mike and Miyajima, Keiichiro and Filzmayer, Maximilian and Merseburger, Axel S and Siech, Carolin and Lauer, Benedikt and Chun, Felix K-H and Koike, Shin and Tohi, Yoichiro and Yanagisawa, Takafumi and Tashiro, Kojiro and Kimura, Takahiro and Urabe, Fumihiko and Mandel, Philipp},
  title = {Cancer‐Control Outcomes of Japanese Vs. German Metastatic Hormone‐Sensitive Prostate Cancer Patients: A Real‐World Cross‐Country Comparison of Patients Undergoing Combination Therapies},
  journal = {International Journal of Urology},
  year = {2026},
  doi = {10.1111/iju.70633}
}
Kostenlos starten →